Congress to Hear Briefing on Kratom Policy Gap and FDA’s 7-OH Distinction

Nearly a year after the FDA drew a distinction between synthetic 7-hydroxymitragynine (7-OH) and natural kratom, federal policy remains absent, leaving states to adopt inconsistent regulations. According to a report by the American Kratom Association, scientists and policy experts will brief Congress on June 3 to address the growing confusion and regulatory gaps surrounding the substance.

The session aims to clarify the FDA’s 2025 recommendation to schedule synthetic 7-OH while preserving access to natural kratom, used by an estimated 20 million Americans. Proposed legislation, including the Federal Kratom Consumer Protection Act, will also be discussed as a pathway to standardized oversight.

More details are available via the original report on Yahoo Finance.